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presence of CAD was 3.0 (95% confidence interval, 1.3 to 7.2; p 
0.02) for the resistin level of 6.0 ng/ml.
In 2004, Burnett et al. (9) reported 74 patients with CAD to have
higher plasma resistin levels than 74 with normal coronary arteries.
Reilly et al. (10) also showed resistin levels to be associated with
coronary calcification by computed tomography in 879 asymptomatic
subjects. We demonstrated resistin levels to be higher in patients with
CAD than in those without CAD and to be an independent factor for
CAD. Moreover, we showed resistin levels to be associated with the
severity of CAD. Our results suggest that serum resistin levels in
patients with CAD reflect the severity of coronary atherosclerosis and
that resistin may play a role in the development of CAD.
Serum resistin levels were reported to be elevated in obese (3)
and diabetic patients (4,5). Resistin levels were also reported to
correlate with BMI (3,5). However, other studies (4,6) and ours
found no such correlation. Silha et al. (6) demonstrated resistin
levels to correlate with fasting insulin levels and HOMA-IR in
obese subjects. Although other studies failed to show such corre-
lations (3,4), we showed significant correlations between resistin
levels and both fasting insulin levels and HOMA-IR in patients
with and without CAD, suggesting a potential link between
resistin and insulin resistance. Interestingly, resistin has structural
similarities to proteins involved in inflammatory processes, espe-
cially FIZZ3, and may be involved in inflammatory processes
associated with obesity (11). Resistin levels were reported to be
associated with plasma CRP and interleukin-6 levels (10,12). We
also showed resistin levels to correlate with hsCRP levels, suggest-
ing a potential link between resistin and inflammation. Because
insulin resistance became recognized to be associated with athero-
sclerotic disease and because atherosclerosis is recognized as a
chronic inflammatory disease, resistin may play some role in
linking insulin resistance and inflammation to CAD.
Our study cannot determine the main source of serum resistin in
patients with CAD and cannot establish causality, because it only
showed some associations. In Figure 1, there was some overlapping in
resistin levels between patients with and without CAD. Serum resistin
levels in patients with CADmay reflect not only coronary atheroscle-
rosis but also the degree of atherosclerosis in other vascular beds.
Thus, serum resistin levels were associated with the presence
and severity of CAD, suggesting that resistin may play a role in the
development of CAD. Resistin levels also correlated with hsCRP
levels and insulin resistance. Resistin may, therefore, play a role in
linking inflammation and insulin resistance to CAD.
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Letters to the Editor
Standard Mutation Nomenclature in
Hypertrophic Cardiomyopathy:
An Urgent Need
The report by Van Driest et al. (1) is the biggest population study
published searching for mutations associated with hypertrophic
cardiomyopathy (389 patients). This type of study is essential to
uncover the genetic basis and molecular spectrum of such a
complex disease.
However, we would like to call attention to two aspects that are
usually forgotten in such studies and that might create confusion.
First, Van Driest et al. (1) report 46 mutations in the MyBPC3
gene, including 33 claimed as “novel.” But at least one of them, the
K811del mutation, has been previously reported by Jaaskelainen et
al. (2); thus, it is not correct to call it “novel.” Moreover, the
mutation W890X was reported in 2004 (3).
Second, it is mandatory to use an unequivocal and unified nomen-
clature system to identify the mutations. Nowadays there is a standard
nomenclature system (4,5) that includes the mention of the reference
sequence employed to numerate the residues, the position of the
mutated nucleotide, and the affected amino acid within the protein.
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None of the mutations reported by Van Driest et al. (1) follow the
admitted nomenclature system, and because of this, in some cases it is
not possible to identify the exact place where the mutation occurs. For
example (Table 1, p. 1906 in their study), the SNPs 2, 23, 30, 34, and
35 cannot be positioned in the reference sequence (it seems to be the
GI:2920822, even though it is not mentioned in the report) because
the investigators only give the amino acid number, and never the
nucleotide. The description of the nucleotide change in essential
because the genetic code is degenerated.
Also, with the use of an equivocal nomenclature system, the
same mutation may be reported in two or more different ways. We
believe that Van Driest et al. consider as novel—because of a
nomenclature error—mutations that have been previously de-
scribed. For example, they refer the SNP 43 as “ins aa G1041fs”;
in this case, it is impossible to determine where the muta-
tion occurs, because the number of the nucleotide where aa is
inserted is not given, but we believe it could correspond to
g.20025_20026insAA T1042fs described by Niimura et al. (6).
The same occurs with the SNPs 8 described by Erdmann et al. (7).
Finally, we have detected similar pitfalls in other published studies
on cardiomyopathies. Because of this, we would like to see an increase
in the quality of the genetic information published on cardiomyopa-
thies by employing the standard mutations’ nomenclature.
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REPLY
In their letter to the editor, Hermida and colleagues illuminate an
issue of ever-increasing importance not only to pathogenetic
studies involving hypertrophic cardiomyopathy (HCM), but for
genomics research as a whole. Their letter calls for standardization
of the format for mutation nomenclature to previously published
recommendations (1,2). Indeed, our laboratory has conformed to
alternate published recommendations (3), and a perusal of the
HCM mutation literature quickly reveals that each laboratory has
developed its own style for mutation reporting.
The pitfalls associated with mutation-formatting inconsisten-
cies are illustrated in our own study (4), where owing to inconsis-
tencies in published mutation nomenclature, three previously
reported mutations in MYBPC3 were mistakenly reported as
novel. The K811del in exon 25 was previously annotated as “exon
25 deletion 3 bp codon 811–815” (5). Exon 13, del c, D389 fs/15
was previously reported as “exon 14 del of c at nt 1200” (6). Finally,
exon 29, ins aa, G1041 fs/5 was previously reported as “Ins
AA1042” (7), and “exon 30, ins of AA at nt 3156” (6). Certainly,
standardization of format as well as nucleotide and exon number-
ing in future publication will enhance data accuracy. However,
several obstacles exist to the implementation of such standardiza-
tion. Nomenclature schemes must be acceptable and, ideally,
required uniformly by all publications. More importantly, any
recognized scheme must be useful for colleagues with diverse
research objectives including linkage analysis, candidate gene
screening, functional characterization, and genetic counseling.
Furthermore, to enable the amalgamation of past mutation data
with current and future discoveries including alternatively spliced
transcripts, large-scale sequence variants, and changing “wild-type”
genetic sequences, a dynamic compendium of sequence data is
required. Indeed, this has been attempted at the genome level with the
National Center for Biotechnology Information database (8), and
tailored specifically for HCM by the Familial HCMDNAMutation
Database (9). Continued submission to, and support of, these re-
sources will enable correlation of the vast data forthcoming with the
foundational groundwork provided by published works. The request for
standardization is much appreciated and has our complete endorsement.
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